Current price is more than the intrinsic value

Intrinsic value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

HDFC, Titan, Tata Consumer, Dabur India, Zydus, Berger Paints, Max Healthcare, Apollo Tyres, and Bajaj Electricals will be among the stocks in focus as they declare their December quarter earnings today.

Stocks to Watch: Adani Enterprises, Britannia, Maruti, Syngene, LIC, TVS

Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing

Biocon sells 9.96% stake in contract research firm Syngene via open market

Syngene International Ltd clocked volume of 400.54 lakh shares by 10:47 IST on BSE, a 2450.39 times surge over two-week average daily volume of 16346 shares

Volumes soar at Syngene International Ltd counter

As of December end, Biocon held 64.5 percent promoter stake in Syngene International. After the block deal, this will go down to 54.5 percent.

Syngene International sees 4 crore shares sold in block deal, Biocon likely seller

Buzzing stocks: Automobile companies Reliance Industries, Tata Motors, Biocon, Syngene International, VOdafone Idea, Ajanta Pharma, Alembic Pharma, Ashok Leyland, Britannia, Gillette, Hindustan Copper, IDFC, Jubilant Foodworks, Kaya, LMW, Mahindra Logistics, Ramco Systems, Raymond, Redington, RPG L…

Stocks that will see action on February 1, 2023

Another growth lever to watch in manufacturing is that of the Mangalore API facility. Here the USFDA approval is expected in H2FY24.

Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch

Q3 Review | Syngene International’s Growth Strategies & Projections For 2023 #Q3WithBQ | Syngene international reports in-line set of earnings, even as revenues see strong growth in Q3.MD & CEO Jonathan Hunt shares projections for Q4 & beyond.

Q3 Review | Syngene International’s Growth Strategies & Projections For 2023

Syngene international reports in-line set of earnings, even as revenues see strong growth in Q3.

MD & CEO Jonathan Hunt shares projections for Q4 & beyond. #BQLive 

-------------------------------------------------------------------------------------------------------------------
For more videos subscribe to our channel: http://bit.ly/32JXa74
Visit BQ Prime for more news: https://www.bqprime.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.bqprime.com/research-reports

For the latest business news and analysis
Subscribe to our Newsletters here: https://www.bqprime.com/my-bq/newsletter
Subscribe to our Telegram channel: https://t.me/BQPrime

Follow BQ Prime here
Twitter: https://twitter.com/bqprime
Facebook: https://www.facebook.com/BQPrime/
LinkedIn: https://www.linkedin.com/company/13184554/
Instagram: https://www.instagram.com/bqprime/
Pinterest: https://in.pinterest.com/BQPrimeNews/

Q3 Review | Syngene International's Growth Strategies & Projections For 2023| BQ Prime

During this quarter, the earnings per share increased to ₹2.73 compared to ₹2.55 in the same quarter last year.

Syngene net profit up 5.9 per cent to ₹109.5 crore

Syngene International reported a 5.5% rise in consolidated net profit to Rs 109.70 crore in Q3 FY23 as against Rs 104 crore posted in Q3 FY22.

Syngene International records PAT of Rs 110 cr in Q3 FY23

Syngene International consolidated net profit rises 5.48% in the December 2022 quarter

Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.

Syngene International Ltd

Syngene International Ltd

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Stocks to Watch: Adani Enterprises, Britannia, Maruti, Syngene, LIC, TVS

Biocon sells 9.96% stake in contract research firm Syngene via open market

Volumes soar at Syngene International Ltd counter

Syngene International sees 4 crore shares sold in block deal, Biocon likely seller

Stocks that will see action on February 1, 2023

Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch

Q3 Review | Syngene International’s Growth Strategies & Projections For 2023

News Video

Q3 Review | Syngene International's Growth Strategies & Projections For 2023| BQ Prime

Syngene net profit up 5.9 per cent to ₹109.5 crore

Syngene International records PAT of Rs 110 cr in Q3 FY23

Syngene International Ltd

Intrinsic valueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry pointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Stocks to Watch: Adani Enterprises, Britannia, Maruti, Syngene, LIC, TVS

Biocon sells 9.96% stake in contract research firm Syngene via open market

Volumes soar at Syngene International Ltd counter

Syngene International sees 4 crore shares sold in block deal, Biocon likely seller

Stocks that will see action on February 1, 2023

Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch

Q3 Review | Syngene International’s Growth Strategies & Projections For 2023

News Video

Q3 Review | Syngene International's Growth Strategies & Projections For 2023| BQ Prime

Syngene net profit up 5.9 per cent to ₹109.5 crore

Syngene International records PAT of Rs 110 cr in Q3 FY23

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock